[go: up one dir, main page]

DK98695A - Fremgangsmåde til solubilisering af iiie-polyanioniske polysaccharider og fremgangsmåde til modificering af neutrale polysaccharider - Google Patents

Fremgangsmåde til solubilisering af iiie-polyanioniske polysaccharider og fremgangsmåde til modificering af neutrale polysaccharider Download PDF

Info

Publication number
DK98695A
DK98695A DK098695A DK98695A DK98695A DK 98695 A DK98695 A DK 98695A DK 098695 A DK098695 A DK 098695A DK 98695 A DK98695 A DK 98695A DK 98695 A DK98695 A DK 98695A
Authority
DK
Denmark
Prior art keywords
polysaccharides
polyanionic
conjugates
solubilizing non
modifying
Prior art date
Application number
DK098695A
Other languages
English (en)
Other versions
DK171951B1 (da
Inventor
Stephen Marburg
Richard L Tolman
Debora A Jorn
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DK98695A publication Critical patent/DK98695A/da
Application granted granted Critical
Publication of DK171951B1 publication Critical patent/DK171951B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DK98695A 1984-12-20 1995-09-07 Fremgangsmaade til solubilisering af ikke-polyanioniske polysaccharider og fremgangsmaade til modificering af de solubiliserede neutrale polysaccharider DK171951B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68440184A 1984-12-20 1984-12-20
US68440184 1984-12-20

Publications (2)

Publication Number Publication Date
DK98695A true DK98695A (da) 1995-09-07
DK171951B1 DK171951B1 (da) 1997-08-25

Family

ID=24747887

Family Applications (2)

Application Number Title Priority Date Filing Date
DK593285A DK171421B1 (da) 1984-12-20 1985-12-19 Polysaccharidforbindelse og fremgangsmåde til fremstilling deraf
DK98695A DK171951B1 (da) 1984-12-20 1995-09-07 Fremgangsmaade til solubilisering af ikke-polyanioniske polysaccharider og fremgangsmaade til modificering af de solubiliserede neutrale polysaccharider

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK593285A DK171421B1 (da) 1984-12-20 1985-12-19 Polysaccharidforbindelse og fremgangsmåde til fremstilling deraf

Country Status (20)

Country Link
US (1) US4830852A (da)
EP (1) EP0186576B1 (da)
JP (1) JPH0825900B2 (da)
KR (1) KR910002704B1 (da)
CN (1) CN1017867B (da)
AT (1) ATE78492T1 (da)
AU (1) AU584149B2 (da)
CA (1) CA1256250A (da)
CY (1) CY1766A (da)
DE (1) DE3586398T2 (da)
DK (2) DK171421B1 (da)
ES (1) ES8701498A1 (da)
GR (1) GR853071B (da)
HK (1) HK18794A (da)
IE (1) IE58977B1 (da)
IL (1) IL77293A (da)
NZ (1) NZ214503A (da)
PT (1) PT81656B (da)
SG (1) SG14294G (da)
ZA (1) ZA859676B (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US6103243A (en) * 1985-05-15 2000-08-15 Biotechnology Australia Pty, Ltd Oral vaccines
EP0270295A3 (en) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Conjugate vaccine
US5116612A (en) * 1987-06-23 1992-05-26 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
DE3785033T2 (de) * 1987-07-21 1993-10-07 Stolle Res & Dev Verfahren zum Erhalten von immunregulierenden Faktoren mittels Säugetierimmunisierung.
DE3889853D1 (de) * 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
JP2921574B2 (ja) * 1988-02-01 1999-07-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンの担体分子としてのｔ細胞のエピトープ
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
DE69033600T2 (de) * 1989-03-09 2001-04-05 American Cyanamid Co., Madison Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
US4963534A (en) * 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
JP2546544B2 (ja) * 1989-10-27 1996-10-23 アーチ ディベラップメント コーポレイション 免疫強化を促進するための方法と組成物
US5466681A (en) * 1990-02-23 1995-11-14 Microcarb, Inc. Receptor conjugates for targeting penicillin antibiotics to bacteria
US5241072A (en) * 1990-05-25 1993-08-31 Genzyne Corporation Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof
CA2047031A1 (en) * 1990-07-19 1992-01-20 Stephen Marburg Peptide-polysaccharide-protein conjugate vaccines
CA2047073A1 (en) * 1990-07-19 1992-01-20 William J. Leanza Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
IL99077A0 (en) * 1990-08-13 1992-07-15 Merck & Co Inc New embodiments of the hiv principal neutralizing determinant and pharmaceutical compositions containing them
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US7279162B1 (en) * 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US5843463A (en) * 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5314811A (en) * 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
JP3917172B2 (ja) * 1992-02-11 2007-05-23 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 二重担体の免疫原性構成体
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
ES2210262T3 (es) * 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
KR100593466B1 (ko) * 1997-01-21 2007-04-25 파스퇴르 메리오 세룸 에 박신 다당류-펩타이드접합체
CA2288267A1 (en) * 1997-04-24 1998-10-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
ES2242421T3 (es) * 1998-09-18 2005-11-01 Binax, Inc. Procedimientos y materriales para la deteccion rapida de streptococcus pneumoniae utilizando anticuerpos purificados especificos de un antigeno.
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US7534442B2 (en) * 2001-08-21 2009-05-19 The Brigham And Women's Hospital, Inc. Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
KR101062525B1 (ko) 2002-11-12 2011-09-06 더 브리검 앤드 우먼즈 하스피털, 인크. 포도상구균 감염에 대한 다당류 백신
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
EP2468769A1 (en) 2004-04-21 2012-06-27 The Brigham and Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
US7842500B2 (en) * 2005-03-31 2010-11-30 Seikagaku Corporation Anti-heparan sulfate antibody, method for detection of heparan sulfate, and kit for detection of heparan sulfate
CA2614640A1 (en) * 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
SG177907A1 (en) 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
CA2673470A1 (en) * 2006-12-21 2008-07-03 Macrogenics, Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
WO2010011284A2 (en) * 2008-07-21 2010-01-28 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
EP2445523B1 (en) * 2009-06-22 2019-04-17 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 8 capsular polysaccharide conjugate immunogenic compositions
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3492661B1 (en) 2016-07-29 2023-11-01 Sumitomo (S.H.I.) Construction Machinery Co., Ltd. Excavator, and control valve for excavator
JP7165468B2 (ja) 2016-11-25 2022-11-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ｎＯＭＶ－抗原コンジュゲート及びその使用
BR112019010227A2 (pt) 2016-11-25 2019-10-08 Glaxosmithkline Biologicals Sa conjugado imunogênico, processo para preparação de conjugado imunogênico, composição imunogênica, vacina, e, uso de nomv
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102028693B1 (ko) * 2017-04-27 2019-10-04 주식회사 유바이오로직스 스트렙토코커스 뉴모니아 협막 다당체의 생산방법
CN107261130A (zh) * 2017-06-29 2017-10-20 云南沃森生物技术股份有限公司 一种用dsc作为活化剂的细菌多糖蛋白结合疫苗的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1115210A (en) * 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8200751L (sv) * 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
JPS58167519A (ja) * 1982-03-30 1983-10-03 Teijin Ltd 細胞毒性複合体及びその製造法
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency

Also Published As

Publication number Publication date
PT81656B (pt) 1988-04-21
ES8701498A1 (es) 1986-12-01
EP0186576A2 (en) 1986-07-02
ZA859676B (en) 1986-08-27
IE58977B1 (en) 1993-12-15
AU5146885A (en) 1986-06-26
PT81656A (en) 1986-01-01
NZ214503A (en) 1990-02-26
SG14294G (en) 1994-06-10
DE3586398D1 (de) 1992-08-27
EP0186576B1 (en) 1992-07-22
ATE78492T1 (de) 1992-08-15
CY1766A (en) 1994-07-15
JPS61186400A (ja) 1986-08-20
HK18794A (en) 1994-03-11
IL77293A (en) 1990-11-05
DK171421B1 (da) 1996-10-21
ES550152A0 (es) 1986-12-01
CN1017867B (zh) 1992-08-19
CA1256250A (en) 1989-06-20
IE853227L (en) 1986-06-20
US4830852A (en) 1989-05-16
JPH0825900B2 (ja) 1996-03-13
DK593285A (da) 1986-06-21
DK171951B1 (da) 1997-08-25
GR853071B (da) 1986-04-21
AU584149B2 (en) 1989-05-18
EP0186576A3 (en) 1989-01-25
KR860004923A (ko) 1986-07-16
CN85108890A (zh) 1986-11-19
DE3586398T2 (de) 1993-01-07
KR910002704B1 (ko) 1991-05-03
DK593285D0 (da) 1985-12-19

Similar Documents

Publication Publication Date Title
DK98695A (da) Fremgangsmåde til solubilisering af iiie-polyanioniske polysaccharider og fremgangsmåde til modificering af neutrale polysaccharider
DK205585A (da) Polysaccharidproteinkonjugat, fremgangsmaade til fremstilling deraf ogpraeparat omfattende et polysaccharidproteinkonjugat
DK121683A (da) Fremgangsmaade til fremstilling af immunoenzymatiske konjugater
DK94783A (da) Fremgangsmaade til fremstilling af kvaternaere 6,11-dihydro-dibenzo-(b,e)-thiepin-11-n-alkyl-norscopinethere og mellemprodukter herfor
DK369287A (da) Immunotoksiner og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende dem
SE8403929L (sv) Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas
DK0454494T3 (da) Calicheamicinoner, derivater deraf og analoge dertil og fremgangsmåde til fremstilling af disse
DK306479A (da) N-cyclohexyl-n-methoxyacetoacetamid, fremgangsmaade til fremstilling deraf og anvendelse deraf til fremstilling af o-methyl-n-cyclohexyl-2,5-dimethylfuran-3-hydroxamsyre
DK440088D0 (da) Fremgangsmaade til fremstilling af n6-benzyloxycarbonyl-2,6-diaminopimelamsyre
DK0661541T3 (da) Fremgangsmåde til fremstilling af langtidsstabile klare sera

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK